EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease

Nuria Tubau-Juni, Raquel Hontecillas iD, Andrew J Leber, Sameeksha S Alva, Josep Bassaganya-Riera iD

Inflammatory Bowel Diseases · 03.04.2024 · 30 (4) · 671-680

DOI: 10.1093/ibd/izad258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 02.11.2023. Verfasst von Nuria Tubau-Juni und 4 weiteren Autor:innen. Beteiligte Einrichtung: NIMML Institute, Blacksburg, VA 24060, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Autoimmune Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: NIMML Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lanthionine synthetase C-like 2 (LANCL2) therapeutics have gained increasing recognition as a novel treatment modality for a wide range of autoimmune diseases. Genetic ablation of LANCL2 in mice results in severe inflammatory phenotypes in inflammatory bowel disease (IBD) and lupus. Pharmacological activation of LANCL2 provides therapeutic efficacy in mouse models of intestinal inflammation, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and psoriasis. Mechanistically, LANCL2 activation enhances regulatory CD4 + T cell (Treg) responses and downregulates effector responses in the gut. The stability and suppressive capacities of Treg cells are enhanced by LANCL2 activation through engagement of immunoregulatory mechanisms that favor mitochondrial metabolism and amplify IL-2/CD25 signaling. Omilancor, the most advanced LANCL2 immunoregulatory therapeutic in late-stage clinical development, is a phase 3 ready, first-in-class, gut-restricted, oral, once-daily, small-molecule therapeutic in clinical development for the treatment of UC and CD. In this review, we discuss this novel mechanism of mucosal immunoregulation and how LANCL2-targeting therapeutics could help address the unmet clinical needs of patients with autoimmune diseases, starting with IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAutoimmune DiseasesHumansAnimalsMiceT-Lymphocytes, RegulatoryMembrane ProteinsPhosphate-Binding Proteins

Stichwörter der Autor:innen

LANCL2LANCL2 therapeuticsTregimmunoregulationinflammatory bowel diseaseomilancor

Substanzen

LANCL2 protein, humanMembrane ProteinsPhosphate-Binding Proteins

Autor:innen und Institutionen

  • NIMML Institute, Blacksburg, VA 24060, USA.

ORCID-Profile: Raquel Hontecillas, Josep Bassaganya-Riera

Förderung

  • NIMML Institute

Zitieren

APA

Tubau-Juni, N., Hontecillas, R., Leber, A. J., Alva, S. S., & Bassaganya-Riera, J. (2024). Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease. Inflammatory Bowel Diseases, 30(4), 671-680. https://doi.org/10.1093/ibd/izad258

Vancouver

Tubau-Juni N, Hontecillas R, Leber AJ, Alva SS, Bassaganya-Riera J. Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease. Inflammatory Bowel Diseases. 2024;30(4):671-680. doi:10.1093/ibd/izad258

BibTeX
@article{TubauJuni2024,
  author = {Tubau-Juni, Nuria and Hontecillas, Raquel and Leber, Andrew J and Alva, Sameeksha S and Bassaganya-Riera, Josep},
  title = {Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {4},
  pages = {671--680},
  doi = {10.1093/ibd/izad258}
}
Kostenlos starten →